Diabetes, obesity & metabolismNov 21, 2024

Heart and kidney effects of using both SGLT2 inhibitors and GLP1 receptor agonists together versus using each alone

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jan 20, 2026

Abstract

Combination therapy of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) is associated with a 57% reduced risk of composite cardiovascular outcomes compared to SGLT2i monotherapy.

Patients receiving the combination therapy showed a reduced risk of composite renal adverse events compared to SGLT2i monotherapy (RR = 0.69).
The combination therapy also resulted in lower risks of composite renal adverse events compared to GLP-1RA monotherapy (RR = 0.66).
Heart failure-related outcomes were less frequent in patients treated with the combination therapy compared to those on GLP-1RA monotherapy (RR = 0.63).
The risk of all-cause mortality was lower in patients receiving the combination therapy compared to those on GLP-1RA monotherapy (RR = 0.66).
These findings suggest that the cardiorenal benefits could be enhanced with combination therapy compared to monotherapy of either agent.

Simplified

OBJECTIVE: This study aimed to evaluate the cardiorenal effect of combining sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) when compared with monotherapy of either agent in patients with type 2 diabetes (T2D).

METHODS: PubMed, Web of Science, Embase, the Cochrane Central Register of Controlled Trials and Clinicaltrial.gov were systematically searched from inception to June 2024. Eligible studies included randomised controlled trials and observational studies assessing that compared with SGLT2i or GLP-1RA monotherapy, the risk of cardiorenal outcomes in patients with T2D who treated with combination therapy. Pooled relative risk (RR) and 95% confidence intervals (CIs) were computed in random-effects model.

RESULTS: In all, five RCTs, 10 post hoc analyses and one observational study were included. The reduced risk of the composite cardiovascular outcome was observed in patients receiving combination therapy of SGLT2i and GLP-1RA when compared with SGLT2i monotherapy (RR = 0.57, 95% CI 0.38-0.86, p = 0.008) or GLP-1RA monotherapy (RR = 0.77, 95% CI 0.65-0.91, p = 0.002). Likewise, the composite renal adverse events were less frequent in patients receiving combination therapy of SGLT2i and GLP-1RA when compared with SGLT2i monotherapy (RR = 0.69, 95% CI 0.59-0.82, p < 0.001) or GLP-1RA monotherapy (RR = 0.66, 95% CI 0.53-0.83, p < 0.001). Compared with GLP-1RA monotherapy, the combination therapy of SGLT2i and GLP-1RA was associated with lower risks of heart failure-related outcomes (RR = 0.63, 95% CI 0.51-0.77, p < 0.001) and all-cause mortality (RR = 0.66, 95% CI 0.50-0.88, p = 0.004) in patients with T2D.

CONCLUSION: The cardiorenal benefits might be magnified with the combination therapy of SGLT2i and GLP-1RA when compared with monotherapy of either agent. Further investigations are needed to validate the findings.

Full Text

Full text is available at the source.

View Full Text ↗

Heart and kidney effects of using both SGLT2 inhibitors and GLP1 receptor agonists together versus using each alone

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief